Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7294   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis

    Summary
    EudraCT number
    		 2018-000331-27
    Trial protocol
    		 GB   DE   CZ   PL  
    Global end of trial date
    03 Dec 2019

    Results information
    Results version number
    		 v1
    This version publication date
    26 Mar 2021
    First version publication date
    26 Mar 2021
    Other versions
    		 v2

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    ANB020-005
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT03533751
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    AnaptysBio, Inc
    Sponsor organisation address
    10421 Pacific Center Court, Suite 200, San Diego, United States, CA 92121
    Public contact
    AnaptysBio Clinical Trials Information, AnaptysBio, Inc, +1 8583626387, clinicaltrialinfo@anaptysbio.com
    Scientific contact
    AnaptysBio Clinical Trials Information, AnaptysBio, Inc, +1 8583626387, clinicaltrialinfo@anaptysbio.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    03 Dec 2019
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    03 Dec 2019
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The main objective of this study was to evaluate the effects of etokimab (ANB020) on skin lesions.
    Protection of trial subjects
    This study was conducted in accordance with the protocol and with the following: • Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines; • Applicable International Council for Harmonisation Good Clinical Practice Guidelines; • Applicable laws and regulations.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    19 Jun 2018
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Canada: 21
    Country: Number of subjects enrolled
    United States: 134
    Country: Number of subjects enrolled
    Germany: 19
    Country: Number of subjects enrolled
    Poland: 47
    Country: Number of subjects enrolled
    Czechia: 46
    Country: Number of subjects enrolled
    United Kingdom: 35
    Worldwide total number of subjects
    302
    EEA total number of subjects
    112
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    279
    From 65 to 84 years
    23
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 This study was conducted in adults with moderate to severe atopic dermatitis (AD). Subjects were randomized on Day 1 to 1 of 5 treatment groups in a 1:1:1:1:1 ratio.

    Pre-assignment
    Screening details
    		 The study had a screening period of up to 4 weeks (Week -4 to 0) prior to administration of study drug on Day 1, treatment period of 16 weeks (Week 0 to 16), and safety follow-up period of 8 weeks (Week 16 to 24).

    Period 1
    Period 1 title
    Randomization Through Start of Treatment
    Is this the baseline period?
    		 No
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Placebo
    Arm description
    		 Subjects randomized to receive matching placebo administered subcutaneously (SC) once every 4 weeks (Q4W) for up to 16 weeks.
    Arm type
    		 Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Period is prior to the start of treatment; no study drug administered.

    Arm title
    		 Etokimab 20 mg Q4W
    Arm description
    		 Subjects randomized to receive etokimab 20 milligrams (mg) administered SC Q4W for up to 16 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Etokimab
    Investigational medicinal product code
    ANB020
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Period is prior to the start of treatment; no study drug administered.

    Arm title
    		 Etokimab 300 mg load + 150 mg Q8W
    Arm description
    		 Subjects randomized to receive etokimab 150 mg administered SC once every 8 weeks (Q8W) following an initial 300 mg loading dose for up to 16 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Etokimab
    Investigational medicinal product code
    ANB020
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Period is prior to the start of treatment; no study drug administered.

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Period is prior to the start of treatment; no study drug administered.

    Arm title
    		 Etokimab 300 mg load + 150 mg Q4W
    Arm description
    		 Subjects randomized to receive etokimab 150 mg administered SC Q4W following an initial 300 mg loading dose for up to 16 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Etokimab
    Investigational medicinal product code
    ANB020
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Period is prior to the start of treatment; no study drug administered.

    Arm title
    		 Etokimab 600 mg load + 300 mg Q4W
    Arm description
    		 Subjects randomized to receive etokimab 300 mg administered SC Q4W following an initial 600 mg loading dose for up to 16 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Etokimab
    Investigational medicinal product code
    ANB020
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Period is prior to the start of treatment; no study drug administered.

    Number of subjects in period 1
    		Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Started
    60
    61
    61
    60
    60
    Completed
    60
    61
    59
    60
    60
    Not completed
    0
    0
    2
    0
    0
         Consent withdrawn by subject
    -
    -
    1
    -
    -
         Lost to follow-up
    -
    -
    1
    -
    -
    Period 2
    Period 2 title
    Treatment Through End of Study
    Is this the baseline period?
    		 Yes [1]
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Placebo
    Arm description
    		 Matching placebo was administered SC Q4W for up to 16 weeks.
    Arm type
    		 Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Placebo was formulated as a sterile solution in single use glass vials containing 1.2 milliliters (mL) of solution.

    Arm title
    		 Etokimab 20 mg Q4W
    Arm description
    		 Etokimab 20 mg was administered SC Q4W for up to 16 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Etokimab
    Investigational medicinal product code
    ANB020
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Etokimab was formulated as a sterile solution in single use glass vials containing 1.2 mL of solution.

    Arm title
    		 Etokimab 300 mg load + 150 mg Q8W
    Arm description
    		 Etokimab 150 mg was administered SC Q8W following an initial 300 mg loading dose for up to 16 weeks. At Weeks 4 and 12, the subjects received a placebo dose.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Placebo was formulated as a sterile solution in single use glass vials containing 1.2 mL of solution.

    Investigational medicinal product name
    Etokimab
    Investigational medicinal product code
    ANB020
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Etokimab was formulated as a sterile solution in single use glass vials containing 1.2 mL of solution.

    Arm title
    		 Etokimab 300 mg load + 150 mg Q4W
    Arm description
    		 Etokimab 150 mg was administered SC Q4W following an initial 300 mg loading dose for up to 16 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Etokimab
    Investigational medicinal product code
    ANB020
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Etokimab was formulated as a sterile solution in single use glass vials containing 1.2 mL of solution.

    Arm title
    		 Etokimab 600 mg load + 300 mg Q4W
    Arm description
    		 Etokimab 300 mg was administered SC Q4W following an initial 600 mg loading dose for up to 16 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Etokimab
    Investigational medicinal product code
    ANB020
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Etokimab was formulated as a sterile solution in single use glass vials containing 1.2 mL of solution.

    Notes
    [1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.
    Justification: Period 1 presents data for all subjects randomized until the start of treatment and Period 2, presents data for all subjects who received study drug. Baseline characteristics are based on subjects who were randomized and who received even a partial dose of study drug; Period 2 is therefore the baseline period.
    Number of subjects in period 2 [2]
    		Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Started
    60
    61
    59
    60
    60
    Completed
    41
    36
    39
    40
    37
    Not completed
    19
    25
    20
    20
    23
         Consent withdrawn by subject
    12
    6
    10
    9
    10
         Physician decision
    -
    2
    1
    2
    1
         Adverse event, non-fatal
    4
    7
    2
    4
    5
         Other
    -
    2
    -
    -
    -
         Miscellaneous
    -
    -
    1
    -
    3
         Prohibited medication
    -
    1
    -
    -
    1
         Lost to follow-up
    3
    7
    5
    4
    3
         Sponsor decision
    -
    -
    1
    1
    -
    Notes
    [2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: Period 1 presents data for all subjects randomized until the start of treatment and Period 2, presents data for all subjects who received study drug. Baseline characteristics are based on subjects who were randomized and who received even a partial dose of study drug; Period 2 is therefore the baseline period.

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo
    Reporting group description
    		 Matching placebo was administered SC Q4W for up to 16 weeks.

    Reporting group title
    Etokimab 20 mg Q4W
    Reporting group description
    		 Etokimab 20 mg was administered SC Q4W for up to 16 weeks.

    Reporting group title
    Etokimab 300 mg load + 150 mg Q8W
    Reporting group description
    		 Etokimab 150 mg was administered SC Q8W following an initial 300 mg loading dose for up to 16 weeks. At Weeks 4 and 12, the subjects received a placebo dose.

    Reporting group title
    Etokimab 300 mg load + 150 mg Q4W
    Reporting group description
    		 Etokimab 150 mg was administered SC Q4W following an initial 300 mg loading dose for up to 16 weeks.

    Reporting group title
    Etokimab 600 mg load + 300 mg Q4W
    Reporting group description
    		 Etokimab 300 mg was administered SC Q4W following an initial 600 mg loading dose for up to 16 weeks.

    Reporting group values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W Total
    Number of subjects
    		 60 61 59 60 60 300
    Age categorical
    Units: Subjects
        In utero
    		 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0
        Newborns (0-27 days)
    		 0
        Infants and toddlers (28 days-23 months)
    		 0
        Children (2-11 years)
    		 0
        Adolescents (12-17 years)
    		 0
        Adults (18-64 years)
    		 0
        From 65-84 years
    		 0
        85 years and over
    		 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    		 39.5 ± 15.92 40.1 ± 16.76 39.7 ± 14.38 38.9 ± 14.61 37.1 ± 14.78 -
    Gender categorical
    Units: Subjects
        Female
    		 29 25 36 24 32 146
        Male
    		 31 36 23 36 28 154
    Race
    Units: Subjects
        American Indian or Alaska Native
    		 0 1 0 0 2 3
        Asian
    		 5 2 0 0 6 13
        Black or African American
    		 6 9 10 4 6 35
        White
    		 49 48 46 55 45 243
        Other
    		 0 1 3 1 1 6
    Ethnicity
    Units: Subjects
        Hispanic or Latino
    		 10 11 8 8 7 44
        Not Hispanic or Latino
    		 50 49 51 50 53 253
        Not Reported
    		 0 1 0 1 0 2
        Unknown
    		 0 0 0 1 0 1
    Height
    Units: centimeter(s)
        arithmetic mean (standard deviation)
    		 169.3 ± 9.40 169.8 ± 10.35 167.7 ± 9.14 173.0 ± 9.25 170.2 ± 9.72 -
    Weight
    Units: kilogram(s)
        arithmetic mean (standard deviation)
    		 76.4 ± 15.67 77.3 ± 14.42 76.0 ± 14.73 78.7 ± 15.03 75.7 ± 15.07 -
    Body Mass Index
    Units: kilogram per meter squared
        arithmetic mean (standard deviation)
    		 26.6 ± 4.73 26.7 ± 4.00 26.9 ± 4.53 26.2 ± 4.27 26.1 ± 4.58 -

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Placebo
    Reporting group description
    		 Subjects randomized to receive matching placebo administered subcutaneously (SC) once every 4 weeks (Q4W) for up to 16 weeks.

    Reporting group title
    Etokimab 20 mg Q4W
    Reporting group description
    		 Subjects randomized to receive etokimab 20 milligrams (mg) administered SC Q4W for up to 16 weeks.

    Reporting group title
    Etokimab 300 mg load + 150 mg Q8W
    Reporting group description
    		 Subjects randomized to receive etokimab 150 mg administered SC once every 8 weeks (Q8W) following an initial 300 mg loading dose for up to 16 weeks.

    Reporting group title
    Etokimab 300 mg load + 150 mg Q4W
    Reporting group description
    		 Subjects randomized to receive etokimab 150 mg administered SC Q4W following an initial 300 mg loading dose for up to 16 weeks.

    Reporting group title
    Etokimab 600 mg load + 300 mg Q4W
    Reporting group description
    		 Subjects randomized to receive etokimab 300 mg administered SC Q4W following an initial 600 mg loading dose for up to 16 weeks.
    Reporting group title
    Placebo
    Reporting group description
    		 Matching placebo was administered SC Q4W for up to 16 weeks.

    Reporting group title
    Etokimab 20 mg Q4W
    Reporting group description
    		 Etokimab 20 mg was administered SC Q4W for up to 16 weeks.

    Reporting group title
    Etokimab 300 mg load + 150 mg Q8W
    Reporting group description
    		 Etokimab 150 mg was administered SC Q8W following an initial 300 mg loading dose for up to 16 weeks. At Weeks 4 and 12, the subjects received a placebo dose.

    Reporting group title
    Etokimab 300 mg load + 150 mg Q4W
    Reporting group description
    		 Etokimab 150 mg was administered SC Q4W following an initial 300 mg loading dose for up to 16 weeks.

    Reporting group title
    Etokimab 600 mg load + 300 mg Q4W
    Reporting group description
    		 Etokimab 300 mg was administered SC Q4W following an initial 600 mg loading dose for up to 16 weeks.

    Primary: Percent Change from Baseline in Eczema Area and Severity Index (EASI) Score

    		 Close Top of page
    End point title
    		 Percent Change from Baseline in Eczema Area and Severity Index (EASI) Score
    End point description
    The EASI is an Investigator assessment measuring the severity of clinical signs in AD. The EASI is considered one of the best validated outcome measures for AD. The EASI score assesses the severity and extent of erythema; induration, papulation, and edema; excoriations; and lichenification. The EASI scores range from 0 to 72, with higher scores indicating greater severity and extent of AD. The full analysis set included all randomized subjects who received 1 dose of etokimab or placebo and had baseline and post-baseline EASI scores.
    End point type
    Primary
    End point timeframe
    Baseline and Week 16
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60
    61
    59
    60
    60
    Units: percent
        least squares mean (standard error)
    -49.38 ± 7.124
    -41.63 ± 6.707
    -55.70 ± 6.206
    -47.40 ± 6.091
    -44.56 ± 7.811
    Statistical analysis title
    		 Placebo Vs Etokimab 20 mg Q4W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline EASI as covariate.
    Comparison groups
    Placebo v Etokimab 20 mg Q4W
    Number of subjects included in analysis
    121
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.4498
    Method
    		 ANCOVA
    Parameter type
    		 Least squares (LS) mean difference
    Point estimate
    7.75
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -12.4066
         upper limit
    		 27.8983
    Variability estimate
    Standard error of the mean
    Dispersion value
    10.235
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q8W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline EASI as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q8W
    Number of subjects included in analysis
    119
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.501
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    -6.32
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -24.774
         upper limit
    		 12.1262
    Variability estimate
    Standard error of the mean
    Dispersion value
    9.39
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q4W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline EASI as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.8349
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    1.97
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -16.6037
         upper limit
    		 20.5476
    Variability estimate
    Standard error of the mean
    Dispersion value
    9.454
    Statistical analysis title
    		 Placebo Vs Etokimab 600 mg load + 300 mg Q4W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline EASI as covariate.
    Comparison groups
    Placebo v Etokimab 600 mg load + 300 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.6662
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    4.82
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -17.1892
         upper limit
    		 26.8275
    Variability estimate
    Standard error of the mean
    Dispersion value
    11.154

    Secondary: Number of Subjects with EASI-50 Responses (≥50% improvement from Baseline)

    		 Close Top of page
    End point title
    		 Number of Subjects with EASI-50 Responses (≥50% improvement from Baseline)
    End point description
    The EASI is an Investigator assessment measuring the severity of clinical signs in AD. The EASI is considered one of the best validated outcome measures for AD. The full analysis set included all randomized subjects who received 1 dose of etokimab or placebo and had baseline and post-baseline EASI scores.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 16
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60
    61
    59
    60
    60
    Units: subjects
    21
    19
    27
    21
    18
    Statistical analysis title
    		 Placebo Vs Etokimab 20 mg Q4W
    Statistical analysis description
    Inferential statistics from a logistic regression model with treatment as fixed effect and baseline EASI as a covariate.
    Comparison groups
    Placebo v Etokimab 20 mg Q4W
    Number of subjects included in analysis
    121
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.7992
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    0.91
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.42
         upper limit
    		 1.9509
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q8W
    Statistical analysis description
    Inferential statistics from a logistic regression model with treatment as fixed effect and baseline EASI as a covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q8W
    Number of subjects included in analysis
    119
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.2197
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.59
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.757
         upper limit
    		 3.3572
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q4W
    Statistical analysis description
    Inferential statistics from a logistic regression model with treatment as fixed effect and baseline EASI as a covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.7197
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.15
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.5345
         upper limit
    		 2.4774
    Statistical analysis title
    		 Placebo Vs Etokimab 600 mg load + 300 mg Q4W
    Statistical analysis description
    Inferential statistics from a logistic regression model with treatment as fixed effect and baseline EASI as a covariate.
    Comparison groups
    Placebo v Etokimab 600 mg load + 300 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.6772
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    0.85
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.391
         upper limit
    		 1.8404

    Secondary: Number of Subjects with EASI-75 Responses (≥75% improvement from Baseline)

    		 Close Top of page
    End point title
    		 Number of Subjects with EASI-75 Responses (≥75% improvement from Baseline)
    End point description
    The EASI is an Investigator assessment measuring the severity of clinical signs in AD. The EASI is considered one of the best validated outcome measures for AD. The full analysis set included all randomized subjects who received 1 dose of etokimab or placebo and had baseline and post-baseline EASI scores.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 16
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60
    61
    59
    60
    60
    Units: subjects
    10
    10
    14
    12
    11
    Statistical analysis title
    		 Placebo Vs Etokimab 20 mg Q4W
    Statistical analysis description
    Inferential statistics from a logistic regression model with treatment as fixed effect and baseline EASI as a covariate.
    Comparison groups
    Placebo v Etokimab 20 mg Q4W
    Number of subjects included in analysis
    121
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.9537
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.03
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.3922
         upper limit
    		 2.6994
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q8W
    Statistical analysis description
    Inferential statistics from a logistic regression model with treatment as fixed effect and baseline EASI as a covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q8W
    Number of subjects included in analysis
    119
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.3316
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.57
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.6323
         upper limit
    		 3.8895
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q4W
    Statistical analysis description
    Inferential statistics from a logistic regression model with treatment as fixed effect and baseline EASI as a covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.5166
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.36
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.5331
         upper limit
    		 3.4944
    Statistical analysis title
    		 Placebo Vs Etokimab 600 mg load + 300 mg Q4W
    Statistical analysis description
    Inferential statistics from a logistic regression model with treatment as fixed effect and baseline EASI as a covariate.
    Comparison groups
    Placebo v Etokimab 600 mg load + 300 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.7426
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.17
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.4545
         upper limit
    		 3.0223

    Secondary: Number of Subjects with EASI-90 Responses (>90% improvement from Baseline)

    		 Close Top of page
    End point title
    		 Number of Subjects with EASI-90 Responses (>90% improvement from Baseline)
    End point description
    The EASI is an Investigator assessment measuring the severity of clinical signs in AD. The EASI is considered one of the best validated outcome measures for AD. The full analysis set included all randomized subjects who received 1 dose of etokimab or placebo and had baseline and post-baseline EASI scores.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 16
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60
    61
    59
    60
    60
    Units: subjects
    3
    5
    7
    7
    2
    Statistical analysis title
    		 Placebo Vs Etokimab 20 mg Q4W
    Statistical analysis description
    Inferential statistics from a logistic regression model with treatment as fixed effect and baseline EASI as a covariate.
    Comparison groups
    Placebo v Etokimab 20 mg Q4W
    Number of subjects included in analysis
    121
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.4543
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.76
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.3998
         upper limit
    		 7.7615
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q8W
    Statistical analysis description
    Inferential statistics from a logistic regression model with treatment as fixed effect and baseline EASI as a covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q8W
    Number of subjects included in analysis
    119
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.1874
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    2.57
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.6314
         upper limit
    		 10.4827
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q4W
    Statistical analysis description
    Inferential statistics from a logistic regression model with treatment as fixed effect and baseline EASI as a covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.1721
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    2.69
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.6506
         upper limit
    		 11.0814
    Statistical analysis title
    		 Placebo Vs Etokimab 600 mg load + 300 mg Q4W
    Statistical analysis description
    Inferential statistics from a logistic regression model with treatment as fixed effect and baseline EASI as a covariate.
    Comparison groups
    Placebo v Etokimab 600 mg load + 300 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.6755
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    0.68
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.1086
         upper limit
    		 4.2141

    Secondary: Number of Subjects who Achieved Validated Investigator’s Global Assessment for Atopic Dermatitis (vIGA-AD) Score Reduction of ≥2

    		 Close Top of page
    End point title
    		 Number of Subjects who Achieved Validated Investigator’s Global Assessment for Atopic Dermatitis (vIGA-AD) Score Reduction of ≥2
    End point description
    The vIGA-AD is a static 5-point scale used to evaluate AD disease severity globally: - 0: Clear - No inflammatory signs of AD (no erythema, no induration/papulation, no lichenification, no oozing/crusting). Post-inflammatory hyperpigmentation and/or hypopigmentation may be present; - 1: Almost clear - Barely perceptible erythema, barely perceptible induration/papulation, and/or minimal lichenification. No oozing or crusting; - 2: Mild - Slight but definite erythema (pink), slight but definite induration/papulation, and/or slight but definite lichenification. No oozing or crusting; - 3: Moderate - Clearly perceptible erythema (dull red), clearly perceptible induration/papulation, and/or clearly perceptible lichenification. Oozing and crusting may be present; - 4: Severe - Marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification. Disease is widespread in extent. Oozing or crusting may be present. Higher scores indicate worse symptoms.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 16
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60 [1]
    61 [2]
    59 [3]
    60 [4]
    60 [5]
    Units: subjects
    8
    7
    8
    10
    9
    Notes
    [1] - Full analysis set.
    [2] - Full analysis set.
    [3] - Full analysis set.
    [4] - Full analysis set.
    [5] - Full analysis set.
    Statistical analysis title
    		 Placebo Vs Etokimab 20 mg Q4W
    Statistical analysis description
    Inferential statistics based on a Logistic regression model with treatment as fixed effect and baseline test score as covariate.
    Comparison groups
    Placebo v Etokimab 20 mg Q4W
    Number of subjects included in analysis
    121
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.6058
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    0.75
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.2481
         upper limit
    		 2.2543
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q8W
    Statistical analysis description
    Inferential statistics based on a Logistic regression model with treatment as fixed effect and baseline test score as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q8W
    Number of subjects included in analysis
    119
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.9521
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    0.97
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.3356
         upper limit
    		 2.7923
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q4W
    Statistical analysis description
    Inferential statistics based on a Logistic regression model with treatment as fixed effect and baseline test score as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.6905
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.23
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.4457
         upper limit
    		 3.3878
    Statistical analysis title
    		 Placebo Vs Etokimab 600 mg load + 300 mg Q4W
    Statistical analysis description
    Inferential statistics based on a Logistic regression model with treatment as fixed effect and baseline test score as covariate.
    Comparison groups
    Placebo v Etokimab 600 mg load + 300 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.9399
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.04
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.3671
         upper limit
    		 2.9518

    Secondary: Number of Subjects who Achieved vIGA-AD Response of 0 (Clear) or 1 (Almost Clear)

    		 Close Top of page
    End point title
    		 Number of Subjects who Achieved vIGA-AD Response of 0 (Clear) or 1 (Almost Clear)
    End point description
    The vIGA-AD is a static 5-point scale to evaluate AD disease severity globally. - 0: Clear - No inflammatory signs of AD (no erythema, no induration/papulation, no lichenification, no oozing/crusting). Post-inflammatory hyperpigmentation and/or hypopigmentation may be present; - 1: Almost clear - Barely perceptible erythema, barely perceptible induration/papulation, and/or minimal lichenification. No oozing or crusting; - 2: Mild - Slight but definite erythema (pink), slight but definite induration/papulation, and/or slight but definite lichenification. No oozing or crusting; - 3: Moderate - Clearly perceptible erythema (dull red), clearly perceptible induration/papulation, and/or clearly perceptible lichenification. Oozing and crusting may be present; - 4: Severe - Marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification. Disease is widespread in extent. Oozing or crusting may be present. Higher scores indicate worst symptoms.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 16
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60 [6]
    61 [7]
    59 [8]
    60 [9]
    60 [10]
    Units: subjects
    5
    5
    6
    8
    6
    Notes
    [6] - Full analysis set.
    [7] - Full analysis set.
    [8] - Full analysis set.
    [9] - Full analysis set.
    [10] - Full analysis set.
    Statistical analysis title
    		 Placebo Vs Etokimab 20 mg Q4W
    Statistical analysis description
    Inferential statistics based on a Logistic regression model with treatment as fixed effect and baseline test score as covariate.
    Comparison groups
    Placebo v Etokimab 20 mg Q4W
    Number of subjects included in analysis
    121
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.7659
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.22
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.329
         upper limit
    		 4.5268
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q8W
    Statistical analysis description
    Inferential statistics based on a Logistic regression model with treatment as fixed effect and baseline test score as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q8W
    Number of subjects included in analysis
    119
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.6273
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.36
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.3895
         upper limit
    		 4.776
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q4W
    Statistical analysis description
    Inferential statistics based on a Logistic regression model with treatment as fixed effect and baseline test score as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.2967
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.88
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.5734
         upper limit
    		 6.1879
    Statistical analysis title
    		 Placebo Vs Etokimab 600 mg load + 300 mg Q4W
    Statistical analysis description
    Inferential statistics based on a Logistic regression model with treatment as fixed effect and baseline test score as covariate.
    Comparison groups
    Placebo v Etokimab 600 mg load + 300 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.5544
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.46
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.4152
         upper limit
    		 5.1476

    Secondary: Number of Subjects who Achieved Numerical Rating System (NRS) for Pruritus Score Reduction from Baseline of ≥4

    		 Close Top of page
    End point title
    		 Number of Subjects who Achieved Numerical Rating System (NRS) for Pruritus Score Reduction from Baseline of ≥4
    End point description
    The NRS for Pruritus is a simple assessment tool that subjects used to report the intensity of their pruritus (itch) during a daily recall period using an ePRO device. Subjects were asked 2 questions: - For average itch intensity: “On a scale of 0 to 10, with 0 being ‘no itch’ and 10 being the ‘worst imaginable itch’, how would you rate your itch overall (on average) during the previous 24 hours?”; - For maximum itch intensity: “On a scale of 0 to 10, with 0 being ‘no itch’ and 10 being the ‘worst imaginable itch’, how would you rate your itch at the worst moment during the previous 24 hours?”. The full analysis set included all randomized subjects who received 1 dose of etokimab or placebo and had baseline and post-baseline EASI scores.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 16
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60
    61
    59
    60
    60
    Units: subjects
    5
    6
    8
    9
    9
    Statistical analysis title
    		 Placebo Vs Etokimab 20 mg Q4W
    Statistical analysis description
    Inferential statistics based on a Logistic regression model with treatment as fixed effect and baseline test score as covariate.
    Comparison groups
    Placebo v Etokimab 20 mg Q4W
    Number of subjects included in analysis
    121
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.86
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.12
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.3175
         upper limit
    		 3.9513
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q8W
    Statistical analysis description
    Inferential statistics based on a Logistic regression model with treatment as fixed effect and baseline test score as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q8W
    Number of subjects included in analysis
    119
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.3222
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.84
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.5511
         upper limit
    		 6.1214
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q4W
    Statistical analysis description
    Inferential statistics based on a Logistic regression model with treatment as fixed effect and baseline test score as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.2564
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.98
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.6089
         upper limit
    		 6.431
    Statistical analysis title
    		 Placebo Vs Etokimab 600 mg load + 300 mg Q4W
    Statistical analysis description
    Inferential statistics based on a Logistic regression model with treatment as fixed effect and baseline test score as covariate.
    Comparison groups
    Placebo v Etokimab 600 mg load + 300 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.2912
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    1.89
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.5806
         upper limit
    		 6.1275

    Secondary: Percent Change from Baseline in Peak Weekly Averaged NRS for Pruritus Score

    		 Close Top of page
    End point title
    		 Percent Change from Baseline in Peak Weekly Averaged NRS for Pruritus Score
    End point description
    The NRS for Pruritus is a simple assessment tool that subjects used to report the intensity of their pruritus (itch) during a daily recall period using an ePRO device. Subjects were asked 2 questions: - For average itch intensity: “On a scale of 0 to 10, with 0 being ‘no itch’ and 10 being the ‘worst imaginable itch’, how would you rate your itch overall (on average) during the previous 24 hours?”; - For maximum itch intensity: “On a scale of 0 to 10, with 0 being ‘no itch’ and 10 being the ‘worst imaginable itch’, how would you rate your itch at the worst moment during the previous 24 hours?”. The full analysis set included all randomized subjects who received 1 dose of etokimab or placebo and had baseline and post-baseline EASI scores.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 16
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    56
    58
    52
    54
    54
    Units: percent
        least squares mean (standard error)
    -21.13 ± 5.964
    -22.30 ± 6.211
    -17.69 ± 6.530
    -30.39 ± 6.176
    -27.18 ± 6.192
    Statistical analysis title
    		 Placebo Vs Etokimab 20 mg Q4W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline Peak Weekly Averaged NRS as covariate.
    Comparison groups
    Placebo v Etokimab 20 mg Q4W
    Number of subjects included in analysis
    114
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.8927
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    -1.17
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -18.2117
         upper limit
    		 15.8686
    Variability estimate
    Standard error of the mean
    Dispersion value
    8.679
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q8W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline Peak Weekly Averaged NRS as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q8W
    Number of subjects included in analysis
    108
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.7035
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    3.43
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -14.2767
         upper limit
    		 21.1463
    Variability estimate
    Standard error of the mean
    Dispersion value
    9.019
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q4W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline Peak Weekly Averaged NRS as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q4W
    Number of subjects included in analysis
    110
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.2819
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    -9.27
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -26.159
         upper limit
    		 7.6237
    Variability estimate
    Standard error of the mean
    Dispersion value
    8.608
    Statistical analysis title
    		 Placebo Vs Etokimab 600 mg load + 300 mg Q4W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline Peak Weekly Averaged NRS as covariate.
    Comparison groups
    Placebo v Etokimab 600 mg load + 300 mg Q4W
    Number of subjects included in analysis
    110
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.4793
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    -6.06
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -22.8452
         upper limit
    		 10.7333
    Variability estimate
    Standard error of the mean
    Dispersion value
    8.557

    Secondary: Percent Change from Baseline in Severity Scoring of Atopic Dermatitis (SCORAD) Scores

    		 Close Top of page
    End point title
    		 Percent Change from Baseline in Severity Scoring of Atopic Dermatitis (SCORAD) Scores
    End point description
    The SCORAD index, a validated assessment of AD, was developed to standardize the evaluation of the extent and severity of AD. There are 3 components to the assessment: - A: extent or affected BSA, assessed as a percentage of each defined body area and reported as the sum of all areas; - B: severity of 6 specific symptoms of AD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, and dryness) is assessed using the following scale: none (0), mild (1), moderate (2), or severe (3); - C: subjective assessment of itch and sleeplessness is recorded for each symptom by the subject on a visual analog scale (VAS), where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness). The SCORAD score is calculated as: A/5 + 7B/2 + C. The maximum score is 103. The full analysis set included all randomized subjects who received 1 dose of etokimab or placebo and had baseline and post-baseline EASI scores.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 16
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60
    61
    59
    60
    60
    Units: percent
        least squares mean (standard error)
    -37.99 ± 4.764
    -31.42 ± 4.605
    -39.22 ± 4.294
    -35.48 ± 4.401
    -31.23 ± 4.927
    Statistical analysis title
    		 Placebo Vs Etokimab 20 mg Q4W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline SCORAD as covariate.
    Comparison groups
    Placebo v Etokimab 20 mg Q4W
    Number of subjects included in analysis
    121
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.3262
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    6.57
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -6.5723
         upper limit
    		 19.7054
    Variability estimate
    Standard error of the mean
    Dispersion value
    6.677
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q8W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline SCORAD as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q8W
    Number of subjects included in analysis
    119
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.8465
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    -1.23
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -13.7439
         upper limit
    		 11.2782
    Variability estimate
    Standard error of the mean
    Dispersion value
    6.366
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q4W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline SCORAD as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.6947
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    2.51
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -10.0587
         upper limit
    		 15.082
    Variability estimate
    Standard error of the mean
    Dispersion value
    6.396
    Statistical analysis title
    		 Placebo Vs Etokimab 600 mg load + 300 mg Q4W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline SCORAD as covariate.
    Comparison groups
    Placebo v Etokimab 600 mg load + 300 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.3288
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    6.76
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -6.8451
         upper limit
    		 20.3626
    Variability estimate
    Standard error of the mean
    Dispersion value
    6.909

    Secondary: Change from Baseline in Dermatology Life Quality Index (DLQI)

    		 Close Top of page
    End point title
    		 Change from Baseline in Dermatology Life Quality Index (DLQI)
    End point description
    The DLQI is a 10-item, validated questionnaire used in clinical trials to assess the impact of AD disease symptoms and treatment on quality of life. The format is a simple response (0 to 3 where 0 is “not at all” and 3 is “very much”) to 10 questions, which assess quality of life (QoL) over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor QoL. The questionnaire was administered only to the subset of subjects who can read and understand a language in which questionnaire is presented (based on availability of validated translations in participating countries). The full analysis set included all randomized subjects who received 1 dose of etokimab or placebo and had baseline and post-baseline EASI scores.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 16
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60
    61
    59
    60
    60
    Units: units on a scale
        least squares mean (standard error)
    -5.61 ± 0.946
    -5.35 ± 0.966
    -6.52 ± 0.945
    -6.05 ± 0.945
    -5.18 ± 1.036
    Statistical analysis title
    		 Placebo Vs Etokimab 20 mg Q4W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline DLQI score as covariate.
    Comparison groups
    Placebo v Etokimab 20 mg Q4W
    Number of subjects included in analysis
    121
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.8497
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    0.26
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -2.4081
         upper limit
    		 2.9218
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.355
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q8W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline DLQI score as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q8W
    Number of subjects included in analysis
    119
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.5016
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    -0.91
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -3.5636
         upper limit
    		 1.7473
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.35
    Statistical analysis title
    		 Placebo Vs Etokimab 300 mg load + 150 mg Q4W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline DLQI score as covariate.
    Comparison groups
    Placebo v Etokimab 300 mg load + 150 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.7511
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    -0.44
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -3.167
         upper limit
    		 2.287
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.386
    Statistical analysis title
    		 Placebo Vs Etokimab 600 mg load + 300 mg Q4W
    Statistical analysis description
    P-value is obtained using mixed effect ANCOVA model with treatment as fixed effect and baseline DLQI score as covariate.
    Comparison groups
    Placebo v Etokimab 600 mg load + 300 mg Q4W
    Number of subjects included in analysis
    120
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.7558
    Method
    		 ANCOVA
    Parameter type
    		 LS mean difference
    Point estimate
    0.43
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -2.3133
         upper limit
    		 3.1824
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.396

    Secondary: Number of Subjects who Experienced an Adverse Event (AE)

    		 Close Top of page
    End point title
    		 Number of Subjects who Experienced an Adverse Event (AE)
    End point description
    An AE is any untoward medical occurrence in a subject or subject, temporally associated with the use of study treatment, whether or not considered related to the study treatment. A treatment-emergent adverse events (TEAEs) is any AE that started or worsened in severity on or after the date and time of the study drug administration. A serious adverse event (SAE) is as any untoward medical occurrence that, at any dose: - Results in death; - Is life-threatening; - Requires inpatient hospitalization or prolongation of existing hospitalization; - Results in persistent disability/incapacity; - Is a congenital anomaly/birth defect. The safety analysis set included all randomized subjects who received 1 dose of etokimab or placebo.
    End point type
    Secondary
    End point timeframe
    Screening up to end of safety follow up period, approximately 24 weeks
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60
    61
    59
    60
    60
    Units: subjects
        Any non-TEAEs
    2
    6
    16
    10
    9
        Any TEAEs
    38
    40
    41
    42
    43
        Any SAEs
    1
    2
    3
    3
    3
        Any TEAEs leading to discontinuation of study drug
    4
    9
    4
    4
    7
        Any TEAEs leading to withdrawal from the study
    4
    7
    2
    4
    5
        Any TEAEs resulting in death
    0
    0
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Subjects with Clinically Significant Changes in Vital Signs Measurements

    		 Close Top of page
    End point title
    		 Number of Subjects with Clinically Significant Changes in Vital Signs Measurements
    End point description
    Body temperature, heart rate, blood pressure, respiratory rate, and weight were assessed. Blood pressure and pulse rate measurements were assessed in the seated position with a completely automated device. Manual techniques were used only if an automated device was not available. Blood pressure and pulse rate measurements were preceded by approximately 5 minutes of rest for the subject in a quiet setting without distractions (e.g., television, cell phones etc.). The safety analysis set included all randomized subjects who received 1 dose of etokimab or placebo.
    End point type
    Secondary
    End point timeframe
    Day 1 up to end of safety follow up period, approximately 24 weeks
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60
    61
    59
    60
    60
    Units: subjects
        Blood pressure increased
    0
    0
    1
    0
    0
        Weight decreased
    0
    1
    0
    0
    0
        Hot flush
    1
    0
    1
    0
    1
        Hypertension
    1
    0
    1
    0
    1
        Palpitations
    0
    0
    2
    0
    0
        Sinus bradycardia
    0
    0
    1
    0
    0
        Angina pectoris
    1
    0
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Subjects with Clinically Significant Changes in Clinical Safety Laboratory Tests

    		 Close Top of page
    End point title
    		 Number of Subjects with Clinically Significant Changes in Clinical Safety Laboratory Tests
    End point description
    Hematology, clinical chemistry, serum pregnancy, follicle-stimulating hormone, urine pregnancy, urinalysis, immunoglobulin, drugs of abuse, viral serology, and tuberculosis testing were performed. The Investigator reviewed the laboratory report and record any clinically significant abnormal laboratory findings occurring during the study were reported as an AE or SAE if applicable. Clinically significant abnormal laboratory findings are those that are not associated with the underlying disease, unless judged by the Investigator to be more severe than expected for the subject’s condition. The safety analysis set included all randomized subjects who received 1 dose of etokimab or placebo.
    End point type
    Secondary
    End point timeframe
    Day 1 up to end of safety follow up period, approximately 24 weeks
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60
    61
    59
    60
    60
    Units: subjects
        Alanine aminotransferase increased
    1
    0
    1
    2
    1
        Aspartate aminotransferase increased
    0
    0
    1
    2
    1
        Blood creatine phosphokinase increased
    3
    1
    0
    1
    1
        Blood lactate dehydrogenase increased
    0
    0
    0
    1
    1
        Blood uric acid increased
    0
    0
    1
    0
    1
        Gamma-glutamyltransferase increased
    2
    0
    2
    0
    0
        Troponin I increased
    0
    1
    0
    0
    1
        Blood glucose increased
    0
    0
    1
    0
    0
        Blood immunoglobulin E increased
    0
    1
    0
    0
    0
        Blood potassium increased
    1
    1
    0
    0
    0
        Urine ketone body present
    0
    0
    0
    0
    1
        White blood cell count increased
    0
    1
    0
    0
    0
        Blood triglycerides increased
    1
    0
    0
    0
    0
        Lymphopenia
    1
    1
    1
    0
    0
        White blood cell disorder
    0
    1
    0
    0
    0
        Hyperlipidaemia
    0
    0
    0
    0
    1
        Hyperuricaemia
    0
    0
    0
    0
    1
        Hyponatraemia
    0
    0
    1
    0
    0
    No statistical analyses for this end point

    Secondary: Number of Subjects with Clinically Significant Changes in Electrocardiogram (ECG) Parameters

    		 Close Top of page
    End point title
    		 Number of Subjects with Clinically Significant Changes in Electrocardiogram (ECG) Parameters
    End point description
    A single 12-lead ECG was obtained using a validated ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT corrected for heart rate using Fridericia's formula (QTcF) intervals. The ECG was reviewed by the Investigator or authorized representative and assessed for clinical significance. The safety analysis set included all randomized subjects who received 1 dose of etokimab or placebo.
    End point type
    Secondary
    End point timeframe
    Day 1 up to end of safety follow up period, approximately 24 weeks
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    60
    61
    59
    60
    60
    Units: subjects
        Electrocardiogram QT prolonged
    0
    0
    0
    0
    1
        Electrocardiogram ST segment elevation
    0
    0
    0
    1
    0
        Electrocardiogram abnormal
    0
    0
    0
    0
    1
    No statistical analyses for this end point

    Secondary: Number of Subjects with Anti-drug Antibodies (ADA)

    		 Close Top of page
    End point title
    		 Number of Subjects with Anti-drug Antibodies (ADA)
    End point description
    Overall status for subjects without positive baseline ADA or neutralizing ADA (NAb). The safety analysis set included all randomized subjects who received 1 dose of etokimab or placebo.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 24
    End point values
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Number of subjects analysed
    0 [11]
    61
    59
    60
    60
    Units: subjects
        ADA positive post-dose
    18
    24
    29
    20
        NAb positive post-dose
    0
    0
    2
    0
    Notes
    [11] - ADA results are not applicable for Placebo arm.
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Day 1 up to Week 16
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    22.0
    Reporting groups
    Reporting group title
    Placebo
    Reporting group description
    		 Matching placebo was administered SC Q4W for up to 16 weeks.

    Reporting group title
    Etokimab 20 mg Q4W
    Reporting group description
    		 Etokimab 20 mg was administered SC Q4W for up to 16 weeks.

    Reporting group title
    Etokimab 300 mg load + 150 mg Q8W
    Reporting group description
    		 Etokimab 150 mg was administered SC Q8W following an initial 300 mg loading dose for up to 16 weeks. At Weeks 4 and 12, the subjects received a placebo dose.

    Reporting group title
    Etokimab 300 mg load + 150 mg Q4W
    Reporting group description
    		 Etokimab 150 mg was administered SC Q4W following an initial 300 mg loading dose for up to 16 weeks.

    Reporting group title
    Etokimab 600 mg load + 300 mg Q4W
    Reporting group description
    		 Etokimab 300 mg was administered SC Q4W following an initial 600 mg loading dose for up to 16 weeks.

    Serious adverse events
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Total subjects affected by serious adverse events
         subjects affected / exposed
    1 / 60 (1.67%)
    2 / 61 (3.28%)
    3 / 59 (5.08%)
    3 / 60 (5.00%)
    3 / 60 (5.00%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    Investigations
    Troponin I Increased
         subjects affected / exposed
    0 / 60 (0.00%)
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 60 (0.00%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Surgical and medical procedures
    Hysterectomy
         subjects affected / exposed
    1 / 60 (1.67%)
    0 / 61 (0.00%)
    0 / 59 (0.00%)
    0 / 60 (0.00%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Dermatitis Atopic
         subjects affected / exposed
    0 / 60 (0.00%)
    0 / 61 (0.00%)
    2 / 59 (3.39%)
    1 / 60 (1.67%)
    3 / 60 (5.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dermatitis Exfoliative Generalised
         subjects affected / exposed
    0 / 60 (0.00%)
    0 / 61 (0.00%)
    0 / 59 (0.00%)
    1 / 60 (1.67%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Joint Instability
         subjects affected / exposed
    0 / 60 (0.00%)
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 60 (0.00%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Cellulitis
         subjects affected / exposed
    0 / 60 (0.00%)
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    0 / 60 (0.00%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eczema Herpeticum
         subjects affected / exposed
    0 / 60 (0.00%)
    0 / 61 (0.00%)
    0 / 59 (0.00%)
    1 / 60 (1.67%)
    0 / 60 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Placebo Etokimab 20 mg Q4W Etokimab 300 mg load + 150 mg Q8W Etokimab 300 mg load + 150 mg Q4W Etokimab 600 mg load + 300 mg Q4W
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    24 / 60 (40.00%)
    22 / 61 (36.07%)
    23 / 59 (38.98%)
    18 / 60 (30.00%)
    26 / 60 (43.33%)
    Investigations
    Blood creatine phosphokinase increased
         subjects affected / exposed
    3 / 60 (5.00%)
    1 / 61 (1.64%)
    0 / 59 (0.00%)
    1 / 60 (1.67%)
    1 / 60 (1.67%)
         occurrences all number
    3
    2
    0
    1
    1
    Nervous system disorders
    Headache
         subjects affected / exposed
    3 / 60 (5.00%)
    5 / 61 (8.20%)
    3 / 59 (5.08%)
    3 / 60 (5.00%)
    1 / 60 (1.67%)
         occurrences all number
    9
    5
    4
    5
    2
    Dizziness
         subjects affected / exposed
    0 / 60 (0.00%)
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    0 / 60 (0.00%)
    3 / 60 (5.00%)
         occurrences all number
    0
    0
    3
    0
    3
    Skin and subcutaneous tissue disorders
    Dermatitis atopic
         subjects affected / exposed
    11 / 60 (18.33%)
    12 / 61 (19.67%)
    6 / 59 (10.17%)
    8 / 60 (13.33%)
    9 / 60 (15.00%)
         occurrences all number
    20
    15
    12
    11
    11
    Eczema
         subjects affected / exposed
    0 / 60 (0.00%)
    1 / 61 (1.64%)
    2 / 59 (3.39%)
    3 / 60 (5.00%)
    5 / 60 (8.33%)
         occurrences all number
    0
    4
    2
    4
    6
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    3 / 60 (5.00%)
    0 / 61 (0.00%)
    1 / 59 (1.69%)
    2 / 60 (3.33%)
    1 / 60 (1.67%)
         occurrences all number
    3
    0
    1
    2
    1
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    4 / 60 (6.67%)
    4 / 61 (6.56%)
    5 / 59 (8.47%)
    5 / 60 (8.33%)
    6 / 60 (10.00%)
         occurrences all number
    7
    4
    6
    8
    7
    Upper respiratory tract infection
         subjects affected / exposed
    3 / 60 (5.00%)
    3 / 61 (4.92%)
    1 / 59 (1.69%)
    2 / 60 (3.33%)
    3 / 60 (5.00%)
         occurrences all number
    5
    3
    2
    4
    5
    Oral herpes
         subjects affected / exposed
    0 / 60 (0.00%)
    0 / 61 (0.00%)
    3 / 59 (5.08%)
    2 / 60 (3.33%)
    1 / 60 (1.67%)
         occurrences all number
    0
    0
    4
    2
    1
    Impetigo
         subjects affected / exposed
    1 / 60 (1.67%)
    0 / 61 (0.00%)
    3 / 59 (5.08%)
    0 / 60 (0.00%)
    0 / 60 (0.00%)
         occurrences all number
    1
    0
    3
    0
    0
    Conjunctivitis
         subjects affected / exposed
    3 / 60 (5.00%)
    1 / 61 (1.64%)
    1 / 59 (1.69%)
    0 / 60 (0.00%)
    0 / 60 (0.00%)
         occurrences all number
    4
    1
    1
    0
    0

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    23 Oct 2018
    Updates included: - Resolution of key comments and requests from respective Regulatory Agencies/Health Authorities; - Procedures were clarified; - Alignment with the Common Protocol Template; - Minor grammatical, editorial, formatting, and administrative changes not affecting the conduct of the study have been incorporated into this amendment for clarification and administrative purposes only.
    02 Jul 2019
    Updates to the statistical approach to data analysis included: - Secondary endpoints were reorganized; - Some previously secondary endpoints were reclassified as exploratory; - Some previously exploratory endpoints were reclassified as secondary; - Timepoints were clarified for some endpoints; - An interim analysis was introduced for analysis of efficacy data at Week 16 and safety data collected as of the date of the data cut-off.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 14 01:06:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA